Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions

被引:20
作者
Adachi, Atsuko
Nagai, Hiroshi
Horikawa, Tatsuya
机构
[1] Hyogo Prefectural Kakogawa Hosp, Dept Dermatol, Kakogawa 6758555, Japan
[2] Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Dermatol, Kobe, Hyogo 657, Japan
关键词
anti-SSA/Ro antibody; acral erythema; discoid lupus erythematosus; fluorouracil; drug eruption;
D O I
10.1159/000096919
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: It is well known that fluorouracil (FU) agents frequently induce discoid-lupus-erythematosus (DLE)-like eruptions and acral erythema in Japan. However, the etiology of these drug eruptions caused by FU agents has not been clarified yet. Objective: To determine if the existence of anti-SSA/Ro antibody may be a risk factor for FU-agent-induced DLE-like eruptions and acral erythema. Patients and Methods: Six patients with FU-agent-induced drug eruptions showing DLE-like lesions and acral erythema were enrolled in this study. The titers of anti-SSA/Ro antibody in the sera and the histopathology of the skin lesions were examined. Results: Biopsy specimens from DLE-like eruptions and all 5 examined acral erythema cases showed lichenoid change of the basal keratinocytes. Direct immunofluorescence studies revealed deposition of immunoglobulins along the basement membrane zone in the lesions of both DLE-like eruptions and acral erythema. Further, all 6 cases had high titers of serum anti-SSA/Ro antibody, which did not decline within 6 months after cessation of the causative drug. Conclusion: We propose that anti-SSA/Ro antibody may be a risk factor for FU-agent-induced drug eruptions showing acral erythema and DLE-like eruptions. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:85 / 88
页数:4
相关论文
共 12 条
[1]   CHEMOTHERAPY-INDUCED ACRAL ERYTHEMA [J].
BAACK, BR ;
BURGDORF, WHC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 24 (03) :457-461
[2]  
Bastida J, 1997, ACTA DERM-VENEREOL, V77, P72
[3]   COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL, FOLINIC ACID, AND ALPHA-INTERFERON PRODUCING HISTOLOGIC FEATURES OF GRAFT-VERSUS-HOST DISEASE [J].
BEARD, JS ;
SMITH, KJ ;
SKELTON, HG .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 29 (02) :325-330
[4]   Terbinafine-induced subacute cutaneous lupus erythematosus [J].
Bonsmann, G ;
Schiller, M ;
Luger, TA ;
Ständer, S .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (06) :925-931
[5]   Terbinafine-induced subacute cutaneous lupus erythematosus [J].
Farhi, D ;
Viguier, M ;
Cosnes, A ;
Reygagne, P ;
Dubertret, L ;
Revuz, J ;
Roujeau, JC ;
Bachelez, H .
DERMATOLOGY, 2006, 212 (01) :59-65
[6]   Animal models of spontaneous and drug-induced cutaneous lupus erythematosus [J].
Furukawa, F ;
Yoshimasu, T .
AUTOIMMUNITY REVIEWS, 2005, 4 (06) :345-350
[7]  
Furukawa F, 1999, HISTOL HISTOPATHOL, V14, P627, DOI 10.14670/HH-14.627
[8]   Association between Discoid Lupus erythematosus and Cigarette Smoking - A case-control study [J].
Miot, HA ;
Miot, LDB ;
Haddad, GR .
DERMATOLOGY, 2005, 211 (02) :118-122
[9]   SUBACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS LESIONS PRECIPITATED BY GRISEOFULVIN [J].
MIYAGAWA, S ;
OKUCHI, T ;
SHIOMI, Y ;
SAKAMOTO, K .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1989, 21 (02) :343-346
[10]   Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus [J].
Srivastava, M ;
Rencic, A ;
Diglio, G ;
Santana, H ;
Bonitz, P ;
Watson, R ;
Ha, E ;
Anhalt, GJ ;
Provost, TT ;
Nousari, CH .
ARCHIVES OF DERMATOLOGY, 2003, 139 (01) :45-49